mail2

NMOtion™ Blog

Discussing NMO Research and Advocacy

Press Release: Alexion Receives FDA Approval Of SOLIRIS® (Eculizumab) For The Treatment Of Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD) Who Are Anti-Aquaporin-4 (AQP4) Antibody Positive

Alexion Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved SOLIRIS® (eculizumab) for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.

Click here to view the full press release.